ACRV Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Acrivon Therapeutics Inc (ACRV) is not a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock is currently in a bearish trend with weak financial performance, no strong trading signals, and limited positive catalysts to support a long-term investment. Holding off on this stock is recommended.
The stock is in a bearish trend with the MACD histogram at -0.0102 and negatively expanding, RSI_6 at 21.62 indicating oversold conditions but no clear signal, and bearish moving averages (SMA_200 > SMA_20 > SMA_5). Key support levels are at 1.466 and 1.384, with resistance at 1.6 and 1.734. The stock closed at $1.4, below its support levels, indicating further downside risk.
The company has cash reserves of $118.6 million, expected to fund operations into Q2 2027.
Additionally, Seeking Alpha's Quant Rating reflects market scrutiny of the company's financial performance.
In Q4 2025, Acrivon reported no revenue growth (0% YoY), a net income loss of -$18.99 million (down -16.85% YoY), and an EPS of -$0.49 (down -18.33% YoY). The company has sufficient cash reserves to fund operations into Q2 2027 but lacks revenue generation.
Piper Sandler raised the price target to $8 from $6 and maintained an Overweight rating, citing promising Phase II data and future IND submission plans. However, no other significant analyst updates or changes in sentiment were noted.
